Apr 16 |
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
|
Apr 12 |
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
|
Apr 10 |
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
|
Apr 9 |
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Mar 21 |
Compass Therapeutics reports FY results
|
Mar 21 |
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
|
Feb 29 |
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
|
Feb 28 |
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
|
Jan 5 |
Compass Therapeutics provides updates regarding ongoing projects
|
Jan 5 |
Compass Therapeutics Provides Corporate Update
|